Glomerulopathy in the KK.Cg-Ay/J Mouse Reflects the Pathology of Diabetic Nephropathy by Stephen P. O'Brien, Mandy Smith, Hong Ling, Lucy Phillips, William Weber, John Lydon, Colleen Maloney, Steven Ledbetter, Cynthia Arbeeny, Stefan Wawersik

“…The KK.Cg-/J (KK-) mouse strain is a previously described model of type 2 diabetes with renal impairment. …”
Get full text

A Spectrum of Age- and Gender-Dependent Lower Urinary Tract Phenotypes in Three Mouse Models of Type 2 Diabetes by Bryce MacIver, Erica M. Bien, Mariana G. de Oliveira, Warren G. Hill

“…Although males exhibited polyuria, neither they nor the females exhibited bladder dysfunction over nine months. KK.Cg-A^y/J males and females were extremely glucose intolerant. …”
Get full text

Meglumine exerts protective effects against features of metabolic syndrome and type II diabetes. by Arturo Bravo-Nuevo, Alice Marcy, Minzhou Huang, Frank Kappler, Jennifer Mulgrew, Lisa Laury-Kleintop, Melvin Reichman, Annette Tobia, George C Prendergast

“…Normal mice (SV129) administered 18 mM meglumine orally for six weeks did not display any gastrointestinal or other observable adverse effects, but had a marked effect on enhancing muscle stamina and at longer times in limiting weight gain. In the established KK.Cg-Ay/J model of non-insulin dependent diabetes, oral administration of meglumine significantly improved glycemic control and significantly lowered levels of plasma and liver triglycerides. …”
Get full text

Matrix metallopeptidase 9 contributes to the beginning of plaque and is a potential biomarker for the early identification of atherosclerosis in asymptomatic patients with diabetes by Bingli Liu, Liping Su, Sze Jie Loo, Yu Gao, Yu Gao, Ester Khin, Xiaocen Kong, Rinkoo Dalan, Xiaofei Su, Kok-Onn Lee, Jianhua Ma, Lei Ye

“…Act-hMMP9 (n=16) or placebo (n=15) was administered to diabetic KK.Cg-Ay/J (KK) mice. Carotid artery inflammation and atherosclerosis measurements were made at 2 and 10 weeks after treatment. …”
Get full text